WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announces the company's key priorities and anticipated catalysts for 2026. "Following another year of strong execution across our portfolio, we enter 2026 positioned for meaningful value-creation and progress,†said Steve Mahoney, President and Chief Executive Officer of Viridian. "The ...